Returning guest, Dr. Gregg Sylvester, Chief Health Officer at CSL Seqirus, one of the world's largest influenza providers, discusses the CDC’s Advisory Committee on Immunization Practices (ACIP) vote around preferred flu vaccines for adults 65+. The vote included Seqirus’ FLUAD ® Quadrivalent as a preferentially recommended seasonal influenza vaccine based on the clinical benefits compared to standard egg-based influenza vaccines. He talks about the implications of this recommendation and how it may translate into improved outcomes for adults 65+, as well as lessen the burden on healthcare systems, expectations for the 2022/23 flu season, choosing a vaccine, and best practices.
#Seqirus
Dr. Gregg Sylvester has led Seqirus Medical Affairs since 2016, overseeing the global team that scientifically differentiates our vaccines by generating Real World Evidence and presenting Seqirus research to national vaccine recommending organizations. Gregg has extensive experience in the pharmaceutical industry, government and patient care. Prior to joining Seqirus, he led Medical Affairs teams in the worldwide launches of Gardasil, Prevnar 13 and Trumenba. Gregg obtained specialty boards in Pediatrics and General Preventive Medicine. Augmenting his clinical expertise, he served in the CDC Epidemic Intelligence Service and as a Public Policy Fellow in the U.S. Congress. During his distinguished career in state government, Gregg was appointed to the Cabinet Secretary for Health and Social Services in Delaware, leading the state’s largest agency. Gregg has an MD from Albany Medical College and an MPH from the Johns Hopkins Bloomberg School of Public Health.
24 июл 2024
